Polymorphism-driven transcriptomic changes in anthelmintic metabolism pathways of Anisakis simplex s.s. L3 larvae Authors: Mateusz Maździarz, Iwona Polak, Lukasz Paukszto, Monika Szczecińska, Elżbieta Łopieńska-Biernat Published: 2025 ABSTRACT AbstractBackgroundHelminth infections continue to pose major challenges in human and veterinary medicine, with additional complications arising from the emergence of anthelmintic resistance. Anisakis simplex sensu stricto (A. simplex s.s.), a zoonotic nematode transmitted through the consumption of fish, is of growing concern due to its allergenic potential and clinical relevance. However, the molecular mechanisms underlying the parasite’s response to anthelmintic treatment remain poorly defined.MethodsThird-stage larvae (L3) of A. simplex s.s. were exposed to three widely used anthelmintics: albendazole (ALB), ivermectin (IVC) and pyrantel (PYR). High-throughput RNA sequencing was combined with differential gene expression, multivariate alternative splicing analysis (Replicate Multivariate Analysis of Transcript Splicing [rMATS] v3.2.5 computational tool) and single nucleotide variant (SNV) profiling with Oxford Nanopore sequencing. Drug-specific effects were assessed across protein-coding genes, long non-coding RNAs (lncRNAs) and splicing events.ResultsDistinct transcriptomic features, including splicing and sequence variants, were observed across treatments, with ALB primarily altering the expression of cuticle-associated genes, IVC inducing extensive alternative splicing in immune-related pathways and PYR exposure linked to widespread SNVs in neuronal projection and metabolic genes. Significant splicing events included exon skipping in the trehalase gene (ALB) and combined skipped exon/alternative 5′ splice site events in moesin/ezrin/radixin-like protein 1 (IVC). A stop/splice-region SNV in trehalose phosphatase was detected with PYR exposure, highlighting coordinated disruption of the trehalose metabolism pathway. Across treatments, 68, 83 and 95 protein-coding genes with allelic variation were identified for ALB, PYR and IVC, respectively, including genes involved in detoxification, oxidative stress, cytoskeletal remodeling and transcriptional regulation.ConclusionsOur findings reveal complex, drug-specific regulatory mechanisms in A. simplex, encompassing transcriptional remodeling, alternative splicing and functional SNVs. Novel modulation of trehalose metabolism and cytoskeletal genes, alongside potential roles for ABC transporters and RNA-binding proteins, suggests diverse adaptive strategies underlying anthelmintic tolerance. This study represents the first integrated transcriptomic and variant-level analysis of Anisakis under drug pressure and provides new insights into molecular resistance mechanisms in marine nematodes, with implications for therapeutic innovation and monitoring strategies.Graphical Abstract Supplementary InformationThe online version contains supplementary material available at 10.1186/s13071-025-07197-w. Background Anthelmintics are the cornerstone of measures aimed at controlling parasitic nematodes affecting humans and animals. Three main groups of anthelmintic drugs, namely macrocyclic lactones (e.g. ivermectin [IVC]), imidothiazoles (e.g. pyrantel [PYR]) and benzimidazoles (e.g. albendazole [ALB]), are commonly used in therapeutic and preventive regimens. Each group targets distinct biological pathways: macrocyclic lactones act on glutamate- and γ-aminobutyric acid (GABA)-gated chloride channels, leading to neuromuscular paralysis; imidothiazoles depolarize muscle membranes by targeting cholinergic receptors; and benzimidazoles inhibit microtubule polymerization and disrupt energy metabolism via fumarate reductase inhibition [1–5]. Despite their broad-spectrum activity, the efficacy of these drugs varies across nematode species and developmental stages. Increasingly, reports of reduced efficacy and drug resistance have emerged from diverse parasitic taxa [6, 7]. Resistance can arise through multiple mechanisms, including point mutations in drug target genes, altered expression of detoxification enzymes (e.g. cytochrome P450 enzymes, glutathione S-transferases [GSTs]) and enhanced efflux via ABC transporters [8–12]. Moreover, resistance is often multifactorial, involving complex regulatory networks that remain poorly characterized in many parasites. Anthelmintics and their efficacy remain controversial and debated across the fields of parasitology and pharmacology. The absence of effective vaccines and limited access to adequate sanitation in many endemic regions hamper the ability to disrupt parasite life-cycles and control transmission [7]. The widespread and repeated use of anthelmintics increases selection pressure, raising the risk of multidrug resistance and treatment failure. Additionally, experiments using in vitro and in vivo models often require non-physiological drug dosages that fail to reflect true pharmacodynamics in parasitic organisms [13]. As a result, there is a growing consensus that next-generation antiparasitic compounds must be designed with species-specific or stage-specific selectivity, taking into account the ecological and biological context of the parasite within its host environment. In this context, Anisakis simplex sensu stricto (A. simplex s.s.) represents a unique challenge. This marine nematode causes anisakiasis in humans following the consumption of raw or undercooked infected fish. Its third-stage (L3) larvae, which are infective to humans, can trigger acute gastrointestinal symptoms as well as allergic reactions [3–5, 14]. The increasing prevalence of Anisakis larvae in commercial fish, combined with the lack of effective treatments, underscores the urgency of understanding its biology and drug susceptibility [14, 15]. While most research on anthelmintic resistance has focused on terrestrial nematodes, marine parasites like A. simplex s.s. remain underexplored. Preliminary studies suggest that conventional drug targets may not be conserved in this species and that exposure to anthelmintics such as IVC or PYR results in transcriptional changes not fully explained by classical mechanisms [8, 16–18]. Results from proteomic and transcriptomic analyses indicate a potentially divergent response to drug pressure, including activation of stress-related proteins and redox pathways [19]. Elucidation of the molecular mechanisms underlying drug response in parasitic nematodes is facilitated by the application of high-throughput transcriptomic approaches that provide a powerful and comprehensive toolkit. Technologies such as RNA sequencing (RNA-Seq) and long-read sequencing enable in-depth analysis of gene expression, alternative splicing and sequence variation—including single nucleotide variants (SNVs)—within the parasite’s transcriptome. Comprehensive knowledge of these features is essential to understand the complex molecular adaptations to anthelmintic pressure [20, 21]. Recent evidence highlights the role of long non-coding RNAs (lncRNAs) and post-transcriptional regulatory mechanisms, such as alternative splicing, in modulating xenobiotic metabolism and stress responses [22]. LncRNAs can influence transcriptional activity, messenger RNA (mRNA) stability and translation efficiency, while alternative splicing may generate distinct protein isoforms with divergent or even opposing functions, potentially altering drug sensitivity or resistance [23, 24]. Together, these regulatory layers offer critical insights into the dynamic response of parasitic nematodes to anthelmintic exposure. In this study, we present an integrative transcriptomic analysis of A. simplex s.s. L3 larvae exposed to three common anthelmintics: ALB, IVC and PYR. Drug-induced changes in gene expression, lncRNA profiles, and alternative splicing were analyzed using short-read sequencing, while single-nucleotide variants (SNVs) were identified using long-read sequencing.. By combining these data, we aim to uncover molecular pathways and regulatory elements involved in drug response, with the long-term goal of informing future monitoring of anthelmintic resistance and the rational design of novel therapeutics for zoonotic nematodes. Methods In vitro culture of A. simplex s.s larvae Third-stage (L3) larvae of A. simplex s. s were isolated from Baltic herring (Clupea harengus membras). Taxonomic identification of the larvae was performed using conventional real-time PCR targeting the internal transcribed spaced (ITS) region, employing the Anis Sensitive Sniper RT-PCR Kit (A&A Biotechnology, Gdańsk, Poland) [16]. The isolated larvae were first thoroughly washed in sterile 0.9% NaCl to remove any contaminants and then cultured in vitro for 12 h in RPMI-1640 medium in 6-well plates under standard conditions (37 °C, 5% CO2, and 95% relative humidity), following the method described by Iglesias et al. [25]. The experiment consisted of a control group (CTR; cultured without drugs but with 0.1% dimethyl sulfoxide [DMSO]) and three treatment groups, with larvae in each treatment group exposed to one of three anthelmintic compounds: IVC (10⁻⁷ M), PYR (10⁻⁶ M) and ALB (10⁻⁶ M). All drugs were dissolved in DMSO, and the final DMSO concentration in both the CTR and treatment groups was adjusted to 0.1% (v/v). The drug doses used in this research were chosen following preliminary studies [8, 16, 19], medicine distributor leaflets and literature review [26–31]. For each drug treatment group and the CTR group, four samples were prepared (10 larvae per sample) and all larvae remained alive throughout the experiment. At the end of the culture period, all larvae were collected and stored at − 80 °C until transcriptome analysis. Preparation of samples and sequencing Transcriptomic analysis of total RNA isolated from L3 larvae of A. simplex s.s cultivated with and without drug treatments was performed using TRIzol reagent. (Cat. No. 15596026; Invitrogen, Thermo Fisher Scientific, Waltham, MA, USA) together with the PureLink RNA Mini Kit (Cat. No. 12183018 A; Invitrogen, Thermo Fisher Scientific) according to the manufacturer’s instructions. RNA quantity and integrity were checked using the Bioanalyzer 2100 and the RNA 6000 Nano LabChip Kit (Cat. No. 5067–1511; Agilent Technologies, Santa Clara, CA, USA). Only high-quality RNA samples with RNA Integrity Number (RIN) > 7.0 were used to generate the sequencing library (L3 CTR group, 4 samples; L3 ALB treatment group, 4 samples; L3 IVC treatment group, 4 samples; L3 PYR treatment group, 4 samples; in total, 16 samples). Approximately 5 µg of total RNA was used to remove ribosomal RNAs using the Ribo-Zero Gold rRNA Removal Kit (Cat. No. MRZG12324; Illumina Inc., San Diego, CA, USA) according to the manufacturer’s instructions. After removal of the ribosomal RNAs, the remaining RNAs were fragmented (Cat. No. E6150S; NEBNext® Magnesium RNA Fragmentation Module, New England Biolabs, Ipswich, MA, USA) into short fragments using divalent cations at a high temperature (94 ℃, 5–7 min). Subsequently, the cleaved RNA fragments were reverse transcribed with SuperScriptTM II Reverse Transcriptase (Cat. No. 1896649; Invitrogen, Thermo Fisher Scientific) to generate complementary DNA (cDNA), which was then used to synthesize U-labeled, second-stranded DNAs with Escherichia coli DNA polymerase I (Cat No. m0209; New England Biolabs), RNase H (Cat. No. m0297; New England Biolabs) and dUTP solution (Cat. No. R0133; Thermo Fisher Scientific). An A-base was then added to the blunt ends of each strand to prepare them for ligation with the indicated adapters. Each adapter contained a T-base overhang for ligation of the adapter to the fragmented A-tailed DNA. The dual-index adapters were ligated to the fragments, and size selection (300–600 bp) was performed using AMPureXP beads (Cat. No. A63881; Beckman Coulter Life Sciences, Indianapolis, IN, USA). After treatment of the U-labeled secondary-stranded DNA with the heat-labile UDG enzyme (Cat No. m0280; New England Biolabs), the ligated products were amplified by PCR under the following conditions: an initial denaturation at 95 °C for 3 min; 8 cycles of denaturation at 98 °C for 15 s, annealing at 60 °C for 15 s and extension at 72 °C for 30 s; and then a final extension at 72 °C for 5 min. The average insert size of the final cDNA libraries was 300 ± 50 bp. Finally, we performed 2 × 150-bp paired-end sequencing (PE150) on an Illumina Novaseq™ 6000 (LC BioTechnology CO., Ltd., Hangzhou, China) according to the manufacturer’s recommended protocol. All bioinformatics analyses (RNA-Seq preprocessing, transcriptome assembly, differential expression, alternative splicing detection and variant calling) were performed using standardized command-line workflows. A complete list of commands, parameters, and options used is provided in Additional file 2: Table S1. Expression profiling The quality of the sequencing was assessed using FastQC software (https://www.bioinformatics.babraham.ac.uk/projects/fastqc; accessed 4 April 2024). After RNA-Seq, Illumina adaptors and poly-A segments were excised using the Trimmomatic v.0.39 trimming tool with the following parameters: CROP:140 LEADING:20 TRAILING:20 MINLEN:140 AVGQUAL:20 (https://www.usadellab.org/cms/? page = trimmomatic) [32]. Reads shorter than 120 nucleotides and with an average Phred quality score < 20 were excluded from the dataset. High-quality FASTQ reads were mapped to the A. simplex PRJEB496 genome reference from WormBase ParaSite using STAR v.2.7.11.a. with the following command parameters: - -outSAMmapqUnique 50 - -outFilterMultimapNmax 20 - -outFilterMismatchNmax 999 - -outFilterMismatchNoverLmax 0.04 - -alignSJoverhangMin 8 - -alignSJDBoverhangMin 1 - -alignIntronMin 20 - -alignIntronMax 1000000 - -alignMatesGapMax 1000000 [33]. The resulting binary alignment map (BAM) files were then used to create annotations with StringTie v2.2.1 [34]. The Ballgown v.2.36 library [35] was then used to quantify expression and perform differential expression analysis between the CTR versus ALB treatment group, CTR versus IVC treatment group and CTR versus PYR treatment group. The genes with low expression were excluded from the study following read counting during the R scripting procedure. The gene-level FPKMs for each sample were estimated using the Ballgown tool. The RNAs with log2FoldChange (log2FC) > 1 and an adjusted p-value (p-adj) < 0.05 were considered to be statistically significant. Subsequently, the identified transcripts were categorized into three groups: (i) differentially expressed genes (DEGs); (ii) differentially expressed long non-coding RNAs (DELs); and (iii) other RNAs. The gene descriptions were assigned using the biomaRt v.2.60.1 [36] package and ENSEMBL annotations [37]. Pearson correlations between the FPKM values for DEGs and DELs were determined using the cor function from the stats v.4.4.1 package in the R environment. The absolute threshold values for this coefficient (Pearson Correlation Coefficient) were > 0.7. Real-time PCR The mRNA level of randomly selected DEGs was determined by real-time PCR according to the general approach described by Polak et al. [16] with modifications. Total RNA was extracted as described in section Preparation of samples and sequencing using the TRIzol reagent in combination with the PureLink RNA Mini Kit (Cat. No. 12183018 A; Invitrogen, Thermo Fisher Scientific) according to the manufacturer’s guidelines. cDNA synthesis was performed using the Invitrogen SuperScript® VILO™ cDNA Synthesis Kit (Cat. No. 11754; Thermo Fisher Scientific Baltics, Vilnius, Lithuania) according to the protocol provided. Specific primers were designed using Primer3Plus software based on sequences from GenBank (Additional file 2: Table S2). The real-time quantitative PCR (qPCR) reactions were prepared using Applied Biosystems™ PowerUp™ SYBR™ Green Master Mix (Cat. No. A25780; Thermo Fisher Scientific Baltics) containing 5 μl of 2× Master Mix, 500 nM of each primer, 10 ng of cDNA and nuclease-free water to a final volume of 10 μl. Amplifications were carried out on a QuantStudio™ 3 Real-Time PCR System (Applied Biosystems™, Thermo Fisher Scientific) in four technical replicates. The reaction conditions were: an initial denaturation at 95 °C for 10 min; followed by 40 cycles of 15 s at 95 °C, 60 s at 60 °C, and 30 s at 72 °C. Reaction specificity was verified by melting curve analysis. The relative mRNA concentrations were quantified using the comparative Pfaffl method [38]. Changes were plotted against the untreated control and normalized against endogenous reference genes: actin (KP200883) and glyceraldehyde-3-phosphate dehydrogenase (KM496565) (relative quantification [RQ] = 1). Results were expressed as means ± standard deviations (SD) and plotted on a log₁₀ scale. Statistical significance for differences in expression of each of the 16 genes was assessed individually using ordinary one-way analysis of variance (ANOVA), followed by Dunnett’s multiple comparison test (comparing each treatment group to CTR) in Prism 10 (GraphPad Software Inc., San Diego, CA, USA), with p-values interpreted as follows: 0.0332 (*), 0.0021 (**), 0.0002 (***) and < 0.0001 (****). Alternative splicing events and differential analysis The Replicate Multivariate Analysis of Transcript Splicing [rMATS] v3.2.5 computation tool (rMATS v.3.2.5 with options -t paired - -readLength 140 - -cstat 0.05) was used to discover differences alternative splicing events (ASEs) based on RNA-Seq raw reads mapped to the reference A. simplex genome [39]. The percent of splicing inclusion (PSI) values was calculated for all alternative splicing events (ASes) according to the reads aligned to the spliced junction sites. The differential alternative splicing events (DASes) between the used medicaments and CTR were statistically tested (false discovery rate [FDR] < 0.05). Moreover, DASes were filtered according to the differential level of the absolute (ΔPSI) > 0.1. The DASes were classified into five subtypes: alternative 5′ splice site (A5SS), alternative 3′ splice site (A3SS), mutually exclusive exons (MXE), retained intron (RI) and skipped exon (SE). Detection of single nucleotide variants and differential analysis SNVs were also examined according to allele frequency differences between the CTR and three experimental treatments. In the first step of the SNV analysis, the mapping results and annotation files were used to carry out variant calling analysis by the bcftools v.1.22 mpileup function [40]. Low-quality variants were filtered out. Allele frequencies were compared directly between the three treatments and CTR using the Weir and Cockerham Fst index [41] as a measure of differentiation. All substitutions with Fst > 0.66 were qualified as significant. The converted VCF file and significant results were intersected using bedtools v.2.30 [42]. Binary alignment map (BAM) files were scanned by Rsamtools v.2.20 software [43] to obtain allele frequency for all significant SNVs. The procedure was repeated for the three anthelmintic drugs (ALB, PYR, IVC). The significant variants were annotated by SNPeff v.4.5 software [44] and further manually selected to the validation procedure. The selection process included: ordering by decreasing coverage in the range of the SNV; repeatability inside the condition; and finally extraction of sequences with a length of 1001 bp (two 500-bp flanking regions and a 1-bp target substitution). Gene ontology Information about gene ontology (GO) was obtained through the eggNOG database [45]. Gene ontologies were searched using coding DNA sequences (CDS) from the A. simplex transcriptome. All DEGs, DASes and SNVs were scanned in this way. Genes were assigned to ontologies when the following criteria were met: Min. hit e-value 0.001, Min. hit bit-score 60, Min. % identity 40, Min. % query coverage 20 and Min. % subject coverage 20 [46]. Visualization The results were visualized using ggplot2 v.3.3.5 [47], circlize v.0.4.15 [48] and circos.ca v.0.69–8 [49] software packages. SNVs were visualized using Geneious Prime software version 2025.0.2 (Biomatters, Auckland, New Zealand). The Sankey diagram was visualized using the ggalluvial library v.0.12.5 [44]. Confirmation SNV Oxford Nanopore sequencing Total DNA was extracted using the Pure™ Cell & Tissue Micro Kit (Cat. No. 090–50; A&A Biotechnology) and quantified prior to amplification. Briefly, 58 single nucleotide polymorphism (SNP) loci were targeted, of which 21 were confirmed in PYR-treated samples, 16 in IVC-treated samples and 21 in ALB-treated samples. Primers were designed to amplify regions containing selected variants using the Primer3Plus web-interface. Confirmatory amplicons were obtained for 31 loci (10 PYR, 10 IVC, 11 ALB); all locus-specific primer sequences for CTR samples are listed in Additional file 2: Table S11. In each PCR reaction volume (25 μl), 4 ng of DNA template and 10 µM of each primer were used in the PCR reactions with GoTaq® G2 Hot Start Master Mix (M7823; Promega, Madison, WI, USA). Cycling conditions consisted of an initial cycle of 94 °C for 2 min; followed by 35 cycles of 94 °C for 15 s, 60 °C for 15 s, 68 °C for 30 s; with a final extension at 68 °C for 1 min. PCR products were purified using the PureLink® PCR Purification Kit (K3100; Invitrogen, Thermo Fisher Scientific) and verified by capillary electrophoresis on the QIAxel system (Qiagen, Hilden, German) with 15 bp/3 kb and 15 bp/2.5 kb markers. Sequencing libraries were prepared using the Oxford Nanopore Native Barcoding Kit 96 V14 (SQK-NBD114.96) following the manufacturer’s two-step ligation protocol (Oxford Nanopore Technologies plc, Oxford, UK): end-preparation, native barcode ligation, adapter ligation and clean-up with. Barcoded libraries were pooled, loaded onto an R9.4.1 flow cell (FLO-MIN106), and sequenced on a MinION Mk1C with MinKNOW v21.03.24 (all Oxford Nanopore Technologies). Raw signal data were base-called with Dorado v0.8 (https://github.com/nanoporetech/dorado), and reads were converted to FASTQ. Filtlong v0.2.1 was used to filter for high-quality reads, which were then mapped to the A. simplex reference genome using minimap2 (v2.30; -ax map-ont). Allele frequencies at polymorphic sites were calculated in Geneious Prime v2025.1.1 using the Find Variation/SNP function. This validation confirmed the presence of RNA-derived polymorphic sites within genomic DNA sequences. Results Comparative analysis of drug-induced transcriptomic alterations The sequences obtained in the RNA-Seq experiment were characterized by very high quality, as evidenced by the following parameters. The average number of reads after filtering (Valid Data) was between 269 and 449 million reads per sample, representing over 97% of the raw reads (Raw Data) classified as valid (Valid Ratio ~ 21–31%). Base quality at the Q20 and Q30 levels was 99.9% and 97.7–97.8%, respectively, indicating an exceptionally low error rate (< 0.1% at Q20, < 0.03% at Q30) (Additional file 2: Table S3). A total of 65, 49 and 29 DEGs in the ALB, IVC and PYR samples, respectively, as well as eight, nine and six DELs in the ALB, IVC and PYR samples, respectively, were identified (Fig. 1; Additional file 2: Table S4). ALB samples contained 29 downregulated and 36 upregulated DEGs, IVC samples contained 20 downregulated and 29 upregulated DEGs and PYR samples contained 10 downregulated and 19 upregulated DEGs. PYR samples showed four downregulated and two upregulated DELs, ALB samples had five downregulated and four upregulated DELs and IVC samples exhibited eight downregulated and one upregulated DEL (Fig. 1; Additional file 2: Table S5). There were 12 common DEGs identified across all three treatments; additionally, 13 DEGs were shared between the PYR and IVC treatment groups, 26 were shared between the IVC and ALB treatment groups and 15 were shared between the ALB and PYR treatment groups (Fig. 1; Additional file 1: Figure S1; Additional file 2: Table S3). Additionally, four common DELs were identified for the PYR and IVC treatment groups, four were identified for the IVC and ALB treatment groups and one was identified for the ALB and PYR treatment groups. The MSTRG.1471.1 transcript DEL was common across all comparisons (Fig. 1; Additional file 1: Figure S2; Additional file 2: Table S4). The analysis of the interdependence between DEL and DEG transcripts showed important positive correlations, indicating a possible regulatory role of lncRNA (Pearson correlation > 0.7). In the ALB group, the strongest correlation (r = 0.76) was observed between the DEL MSTRG.1471 and the DEG encoding the protein AT04676p, which was identified on the basis of orthology to Drosophila melanogaster. The second strong link was the MSTRG.1342–mRNA O-acyltransferase pair (Additional file 2: Table S6). In the case of IVC, the DELs MSTRG.4373 and MSTRG.886 correlated strongly with the mRNA encoding 1,2-dihydroxy-3-chain-5-methylthene dioxygenase, while MSTRG.1095 and MSTRG.5177 correlated with a transcript encoding a protein with the domain BPI2 (Additional file 2: Table S7). In response to PYR, DEL MSTRG.886 correlated strongly with mRNA metalloendopeptidase (Additional file 2: Table S8). These results indicate potential drug-specific transcriptional interactions between non-coding and coding transcripts. Notably, several genes with putative functions in cuticle formation, oxidative stress response and xenobiotic metabolism exhibited marked changes in expression. For example, a gene annotated as Col_cuticle_N domain-containing protein showed a substantial increase in expression (log2FC = 1.14), suggesting a possible role in modifying cuticular structure or permeability as an adaptive response to the three drugs. Conversely, under ALB treatment some peroxidasin-like transcripts were downregulated, potentially reflecting a suppressed oxidative defense mechanism (Additional file 2: Table S6). Comparison of DEG and DEL expression in response to drugs. The Circos chart shows a comparison of DEGs and DELs. The outermost track, or heatmap, displays z-scored expression values. The second track, a line graph, represents drug comparisons, with blue for ALB, green for IVC and red for PYR. The next track is a scatter plot showing log2FC values, where red dots indicate upregulated genes and blue dots indicate downregulated genes. The center of the chart features links that highlight the shared components: black for ALB and PYR DEGs, red for ALB and IVC DEGs, green for IVC and PYR DEGs, blue for ALB and PYR DELs, purple for ALB and PYR DELs and orange for IVC and PYR DELs. ALB, Albendazole; DEGs, differentially expressed genes; DELs, differentially expressed long-non-coding genes; IVC, ivermectin; PYR, pyrantel Results from the RNA-Seq approach were confirmed using real-time PCR, which was used to demonstrate the expression of 16 randomly selected RNAs. Molecules for the validation were selected according to their functionality, expression levels and distribution across samples. There was a strong agreement (Pearson’s r = 0.85, p-value = 0.0039) between the RNA expression data obtained by real-time PCR and the RNA-Seq results (Additional file 1 Figures S3, S4; Additional file 2: Table S2). Differential alternative splicing under anthelmintic exposure A comparable number of ASEs were detected across treatments, with 2997, 2992 and 2711 ASEs under the ALB, PYR and IVC treatments, respectively. However, the number of DASes varied, being highest in the IVC treatment group (n = 15), followed by the PYR treatment group (7) and the ALB treatment group (5) (Fig. 2; Additional file 2: Table S9). In the ALB-treated group, five significant DASes were identified, including A3SS in ASIM_0001014601 (ZC3H12A; ΔIncLevel = – 0.223; FDR = 0.024), and SE events in genes encoding a trehalase-like protein, a RING finger protein and a moesin/ezrin/radixin-like protein. An unannotated gene (MSTRG.17504) also exhibited A3SS (ΔIncLevel = + 0.548; FDR = 0.01), indicating regulation of stress, protein degradation and cytoskeletal organization (Fig. 2; Additional file 1: Figure S5; Additional file 2: Table S9). The IVC group showed the widest ΔPSI range (+ 0.616 to – 0.556) and included splicing alterations in genes involved in RNA processing, membrane transport and intracellular signaling. Notable examples were SE events in ASIM_0001057901, ASIM_0001291601, and A5SS in MSTRG.17302. Recurring A3SS and A5SS events were found in MSTRG.13784 (zinc finger protein; ΔIncLevel = – 0.315) and MSTRG.21923 (PH domain-containing protein; ΔIncLevel = + 0.609) (Fig. 2; Additional file 1: Figure 6; Additional file 2: Table S9). In the PYR group, seven DASes were observed, including SE in ASIM_0001079101 (ΔIncLevel = – 0.583; FDR = 0.01) and A5SS in MSTRG.16329 (ΔIncLevel = + 0.265) (Fig. 2; Additional file 1: Figure S7; Additional file 2: Table S9). Splicing changes affected genes associated with ion transport (MSTRG.12187), extracellular matrix remodeling (MSTRG.20748) and metabolite transport (MSTRG.15994, MXE in YwtG-like transporter) (Fig. 2; Additional file 2: Table 9). Circular heatmaps illustrate the associations between significant splicing events across three comparisons: IVC, ALB and PYR treatment groups. The heatmaps display the percentage of inclusion for each comparison within three separate blocks (green scale for IVC, red scale for ALB and blue scale for PYR). The second track depicts the difference values (∆PSI) of higher (red) and lower (blue) DASes in each compared group. The third track presents the types of alternative splicing events, where green represents SEs, blue represents A3SSs, yellow represents A5SSs and purple represents MXEs. The inner track shows the correlation links between each group, where pink links depict intersected genes for IVC and PYR DASes, gold depict intersected genes for ALB and PYR DAS events and blue links depict intersected genes after ALB and IVC treatment. A3SS, Alternative 3′ splice site' A5SS, alternative 5′ splice site; ALB, albendazole; AS, alternative splice; DASes, differential alternative splicing events; IVC, ivermectin; MXE, mutually exclusive exons; PSI, percent of splicing inclusion; PYR, pyrantel; SE, skipped intron; RI, retained intron Allele-specific variant profiling and transcriptomic responses to ALB, IVC and PYR In the experimental model, 603,522, 566,305 and 591,284 SNVs were identified following the in vitro exposure of larvae to ALB, IVC and PYR, respectively. After allele frequency comparisons between the experimental (treatment) samples and CTR, 3273, 3086 and 1794 outliers (heterozygous positions) for ALB, IVC and PYR were followed to the next stage of analysis. The downstream filtration steps (sum of coverage for each position > 30) qualified 74 SNVs after ALB treatment. After the application of IVC, the same filtration step as that for Anisakis transcriptome screening revealed 107 substitutions that changed its allele frequency. Analysis of the third experimental anthelmintic (PYR) identified 92 SNVs as potential candidates of allelic specific variants. Nine, four and one of the SNVs had similar allelic frequency changes between IVC/PYR, ALB/PYR and ALB/IVC, respectively. Three of the significant substitutions were common for all treatments applied. The 68 protein coding genes were potential candidate targets of transcriptomic response for the ALB treatment. The two other anthelmintics involved transcriptomic modulations of 83 (PYR treatment) and 95 (IVC treatment) protein coding transcripts. Based on genomic localization, the highest imbalance of allele expression between the ALB/PYR/IVC-treated groups and the Anisakis CTR were detected within A-to-G and C-to-T substitutions. SnpEff assigned allelic-specific expression candidates to the following main variant consequences: upstream gene variants (n = 8), 5′ UTR variants (n = 4), 3′ UTR variants (n = 1), missense (n=32), synonymous (n=131, intron variant calling (n=71), stop lost (n=2), splice region variant (n=13), start retained variant/stop retained variant (n=1) and downstream variant (n=20). S—s. (Fig. 3; Additional file 2: Table S10). A circular chart illustrates the associations between single nucleotide variants (SNVs) across three comparisons: ivermectin (IVC; green background), albendazole (ALB; red background) and pyrantel (PYR; blue background). The outermost track depicts the Anisakis simplex gene accessions. The histogram tracks display the frequency of alternative and reference variants within treated samples (A, C) and control samples (B, D). Track E presents a line graph of the FST indicator (threshold > 0.66). The subsequent eight middle scatter tracks represent SNVs located within the upstream gene region (F), 5′ untranslated region (UTR) (G), those causing missense effects (H), those causing synonymous effects (I), intron regions (J), 3’ UTR regions (K), downstream gene regions (L) and other modification types (M). The innermost track shows the correlation links between experimental groups. Red links indicate intersected genes with SNVs for trials involving ALB and PYR, green links describe intersected genes with SNVs for trials involving IVC and PYR and blue links illustrate intersected genes with SNVs for trials involving ALB and IVC Allele frequency validation using nanopore sequencing We identified 29 SNVs among three drug-treated groups (IVC, ALB, PYR) and their respective CTR group. Each SNV is defined by its contig position, reference nucleotide (Ref), alternate nucleotide (Alt) and variant allele frequency (VAF), evaluated in both the treated and CTR groups. In all three treatment groups, SNVs demonstrated significant alterations in allele frequency between the treated groups and the CTR. In the IVC experiment, six out of 10 SNVs demonstrated reduced VAF in treated samples compared to the CTR (e.g. ASIM_scaffold0000920:14012 A → C), whereas four SNVs displayed elevated VAF following treatment (e.g. ASIM_contig0004408:1203 C → T). Similar patterns of enrichment and depletion of variant alleles were seen in the ALB and PYR trials (Additional file 2: Table S11). Both a reference and an alternative variant were identified for all SNV positions detected, confirming the presence of a heterozygous SNV (genotype 0/1). Nanopore sequencing allowed the estimation of the presence of variant alleles (VAF, frequency allele), with many positions showing an almost even distribution (approx. 50:50), confirming their heterozygous character and allowing further analysis of allele-specific gene expression. The identification of SNVs in regions affecting splicing (e.g. SPLICE region, STOP/SPLICE) enabled recognition of potential functional changes in transcript modification. These findings confirm the presence of polymorphic areas in genomic DNA linked to RNA polymorphisms, demonstrating drug-specific variations in allele frequencies indicative of selecting pressures (Additional file 2: Table S11). Multiomic analysis of drug impact on GO terms related to immune system response, cuticle development and neuron projection guidance in A. simplex The GO terms were assigned to the A. simplex transcripts. Three processes were focused on: immune system process (GO:0002376), cuticle development (GO:0042335) and neuron projection guidance (GO:0097485). Multiomics regulations of these three processes were identified by combining results from the SNV, DEG and DAS analyses (Fig. 4; Additional file 1: Table S5). In the case of cuticle development, ALB, IVC and PYR were found to differ in the number of molecules influencing this process. IVC and PYR drugs were associated with a larger number of molecules related to cuticle development, while ALB showed a slightly lower diversity of molecules. For example, ALB was linked to five molecules related to DEGs and one molecule related to SNVs, whereas IVC contained one molecule related to DEGs and 3 molecules related to SNVs. PYR was associated with one molecule related to DEGs and two molecules related to SNVs. Regarding immune system processes, the drugs ALB, IVC and PYR also differed in the number of molecules influencing this process. ALB was linked to two molecules associated with DASes and DEGs, as well as four molecules related to SNVs. For IVC, the number of molecules varied, including three molecules related to DASes, two molecules related to DEGs and seven molecules related to SNVs. PYR contained one molecule related to DASes and six molecules related to SNVs. In the case of neuron projection guidance, the drugs ALB, IVC and PYR also differed in the number of molecules influencing this process. ALB was linked to one molecule related to DASes and two molecules related to DEGs; IVC contained one molecule related to DASes and three molecules related to SNVs; and PYR was associated with one molecule related to DASes and five molecules related to SNVs. In summary, the drugs IVC and PYR contained significantly more molecules associated with various biological processes, particularly in the context of processes such as cuticle development, immune system and neuron projection guidance. ALB exhibited a lower diversity of molecules in these processes, which may indicate the specific mechanisms of action for each drug (Fig. 4; Additional file 2: Table S12). Sankey diagram illustrating the relationships between the identified GO terms, DEGs, DASes and SNVs. The “A. simplex gene id” column provides gene identifiers. The “Medicine” column corresponds to the drug in which a significant result was detected. The “Analysis” column contains information about the molecule, indicating whether it was DEG, DAS or SNV. The “Term” column corresponds to the selected four GO processes. Blue links are correspond to PYR, orange links correspond to ALB and green links correspond to IVC. ALB, Albendazole; DASes, differential alternative splicing events; DEGs, differentially expressed genes; GO, gene ontology; IVC, ivermectin; PYR, pyrantel; SNV, single nucleotide variant Discussion Anthelmintic resistance in parasitic nematodes is a multifactorial phenomenon driven by genetic, transcriptomic and epigenetic mechanisms. Recent studies have identified several genetic factors contributing to resistance, including differential gene expression, SNPs and alternative splicing events. In the red stomach worm Haemonchus contortus, comparisons between resistant and susceptible strains revealed distinct gene expression patterns, although high genetic variability complicates interpretation of the results [50]. Moreover, lncRNAs have been linked to ALB resistance in this nematode species [22], while SNPs affecting splicing have been implicated in gastrointestinal nematode resistance in sheep, particularly in immune and sterol metabolism pathways [24]. In the brown stomach worm Teladorsagia circumcincta, upregulation of the P-glycoprotein gene Tci-pgp-9 in all life stages, especially in eggs, suggests a role in IVC resistance [12]. In the present study, we applied high-throughput transcriptomic and variant analysis to investigate the response of Anisakis simplex s.s. L3 larvae to three anthelmintic compounds: ALB, IVC and PYR. We identified drug-specific transcriptomic signatures related to cuticle formation, neuronal development and immune processes, with ALB mainly regulating cuticle-associated genes through DEGs, IVC inducing AS in immune-related genes and PYR causing numerous SNVs across all functional categories. These results suggest both overlapping and distinct mechanisms of drug response in A. simplex. Differential gene expression in the treated larvae affected genes involved in cuticle biosynthesis, oxidative stress response and xenobiotic metabolism—findings consistent with those of studies in other nematodes [51–53]. Notably, we detected exon skipping in trehalase and complex splicing (SE/A5SS) in moesin/ezrin/radixin-like protein 1 (MERP1) in larvae exposed to ALB and IVC. Although not previously reported in nematodes, such ASes are reminiscent of resistance-related splicing changes in H. contortus (e.g. acr-8) [54–56] and apicomplexan parasites [57] and efflux pump regulation in fungi under antifungal stress [58]. In A. simplex, trehalase AS may impact energy homeostasis, while MERP1 may influence cytoskeletal remodeling during drug stress. Notably, the threonine residue (merlin T251, ezrin T235, radixin T235, moesin T235), which is conserved across all merlin–ezrin–radixin–moesin (ERM) proteins, is conservatively substituted by serine in nematode ERMs [59]. We also identified a splice-region SNV in trehalose phosphatase, a key enzyme in trehalose biosynthesis. In the roundworm Caenorhabditis elegans, deletion of its ortholog gob-1 is embryonically lethal [60, 61] and in the nematode Brugia malayi, the trehalose pathway is upregulated in infective stages [62]. The co-occurrence of SNVs and ASes in this pathway suggests stress-induced destabilization of trehalose metabolism, potentially as a strategy to redirect energy use or counter osmotic and oxidative stress. These results align with our previous work demonstrating changes in trehalose synthesis enzyme activity in A. simplex following drug treatment [63, 64]. We cross-referenced our key findings (e.g., trehalase, trehalose phosphatase, ABCA2, MERP1) with the WormBase ParaSite and confirmed the conservation of orthologs and splice-associated domains [65]. Importantly, Variant Effect Predictor (VEP) annotations indicated that SNVs occurred in or near conserved splice motifs, further supporting their potential regulatory relevance [66]. Our SNV analysis revealed multiple missense mutations in genes involved in detoxification (e.g. ACSL5, serine carboxypeptidase, PEPCK), oxidative stress (e.g. SOD1, cyclophilin), drug transport (e.g. ABCA2, MFS10), gene regulation (e.g. RNA-binding proteins, ZNF, WDR4), cytoskeletal organization (dynein, ZIP transporter) and genome stability (integrase-like, RIH-domain proteins). These findings are consistent with previous reports linking ABC transporter mutations to IVC resistance in H. contortus and Onchocerca volvulus [67–71]. Similarly, oxidative stress genes like SOD1 and glutathione S-transferases are involved in the response to IVC and PYR in Pseudoterranova and Contracaecum [8, 16]. Regulatory and non-coding variants add a layer of post-transcriptional control. In our dataset, we detected 71 intronic and 13 splice-region SNVs affecting genes involved in metabolism, signaling and stress response. Intronic variants may interfere with splicing enhancers or silencers, while SNVs within canonical splice sites can abrogate proper exon–intron recognition, potentially altering transcript stability or isoform diversity [66]. Among the genes impacted by these variants were ABC transporters, oxidoreductases, serine carboxypeptidase S28 and HDAC1, all of which are implicated in drug efflux, detoxification, and epigenetic regulation. Such changes could have functional consequences for xenobiotic metabolism, contributing to altered drug susceptibility or resistance phenotypes [72–74]. The strong positive associations with specific mRNA genes identified in the correlation analysis of the lncRNA transcript suggest the existence of drug-specific regulatory mechanisms. In the response to ALB, the correlation of MSTG.1471 with transcript AT04676p (protein with a putative function in the cytoskeleton) and of MSTRG.1342 with O-acyltransferase may indicate the involvement of this lncRNA in cytoskeletal homeostasis and lipid metabolism under conditions of structural destabilization by ALB [75, 76]. In the case of IVC, correlations of the DELs MSTRG.4373 and MSTRG.886 with the enzyme of the methionine salvage pathway (1,2-dihydroxy-3-keto-5-methylthiopentene dioxygenase) as well as between MSTG.1095 and MSTRG.5177 and a BPI2 domain-containing protein suggest the activation of detoxification mechanisms and prevention of oxidative stress [7, 77, 78]. In response to PYR, the association of MSTG.886 with a metalloendopeptidase may reflect involvement in proteolytic and adaptive processes in target tissues of the drug, such as neurons and muscles [79]. Additionally, 5′/3′ UTR and up- or downstream SNVs were found in genes related to signaling (Piezo1), translation (ribosomal S7, RFC), vesicle transport (kinesin, Tomosyn-like) and proteostasis (DnaJ, interferon-like proteins), suggesting roles in transcript stability, translation efficiency or transcriptional regulation [80]. These findings support the theory that lncRNAs and non-coding regulatory regions are involved in modulating the transcriptomic plasticity of A. simplex in response to drug exposure, possibly through mechanisms analogous to those in other helminths [81, 82]. Although our findings provide valuable insights, they are based on cross-sectional data and require validation in larger, longitudinal cohorts to capture gene expression dynamics over time. Future studies should include more larvae to strengthen generalizability. SNV calling was performed on RNA-Seq reads mapped to the A. simplex reference genome rather than on DNA-Seq data aligned to a complete genomic assembly. As a result, these variant calls may be affected by mapping artifacts, RNA editing, allele-specific expression and incomplete transcript representation and should therefore be interpreted with caution. Nonetheless, a key strength of our study is that, even with only four larvae per group, we detected consistent and biologically meaningful differences between groups. Integrating metabolomic and lipidomic data could further provide a comprehensive systems-level understanding of A. simplex responses to drug treatment. Conclusions While our study provides the first integrative transcriptomic analysis of Anisakis simplex L3 larvae exposed to three anthelmintics (ALB, IVC, and PYR), several limitations shape the interpretation of our results and define future research priorities. A key constraint in Anisakis research is the inability to culture resistant and susceptible isolates, making classical resistance models inapplicable. Consequently, rather than comparing resistant versus susceptible strains, future studies should focus on functional validation of the candidate molecular markers identified in the present study (e.g. SNVs in trehalose metabolism, ABC transporters or splicing-related genes). Approaches such as RNAi knockdown or heterologous expression in model nematodes (e.g. C. elegans) could help test the impact of these variants on drug sensitivity. Moreover, while long-read nanopore sequencing enabled detection of full-length isoforms and haplotypes, its error rates in homopolymer regions may limit SNV accuracy. Refining these data with hybrid sequencing or improved basecalling algorithms could enhance variant resolution. To further understand adaptive responses, future research should: (i) apply time-course transcriptomic profiling to distinguish between early stress responses and stable transcriptomic remodeling; (ii) explore epigenetic and ncRNA mechanisms, given the observed lncRNA–mRNA correlations with drug-response genes; (iii) incorporate proteomic and metabolomic data to link gene regulation with parasite physiology and fitness under drug pressure; and (iv) investigate environmentally driven population variability to infer natural selection signatures associated with drug exposure in the wild. In the absence of experimental selection, these integrative, multi-omics and functional approaches offer the most promising path forward to elucidate the molecular basis of drug tolerance and support surveillance strategies in zoonotic marine nematodes. The identification of drug-specific transcriptomic signatures and regulatory elements in A. simplex provides a foundation for the rational design of next-generation anthelmintics. Candidate pathways such as trehalose metabolism, ABC transporter systems, alternative splicing machinery and cytoskeletal remodeling proteins emerged as key nodes of drug response and may serve as novel therapeutic targets. Furthermore, SNVs and expression profiles linked to detoxification or stress responses can inform the development of drug combinations that circumvent compensatory resistance mechanisms. The lncRNA–mRNA correlations also highlight the potential of targeting ncRNA-mediated regulation as an innovative antiparasitic strategy. These insights are particularly valuable for zoonotic marine nematodes, where drug development is challenged by a lack of genomic resources and experimental models, and could guide the discovery of compounds with enhanced efficacy or broader antihelminthics activity. Supplementary Information Additional file 1: Figure S1. The Venn diagram illustrates the number of DEGs and the common DEGs in the ALB, IVC, PYRcolor comparisons. Figure S2. The Venn diagram illustrates the number of DELs and the common DELs in the ALB, IVC, PYRcolor comparisons. Figure S3. The results of correlations analysis between RT-PCR method and RNA-Seq. Selected DEGs were marked with different color for each treatment comparison. The Y-axis shows the log2 obtained by the RNA-seq method, while the X-axis shows the log2 of validated DEGs measured by the qPCR method. Details can be found in Additional file 2: Table S2. Figure S4. Relative expression levels of genes in response A. simplexto drug treatmentscompared to control, as determined by quantitative real-time PCR. mRNA expression of each genewas normalized to housekeeping gene expression and expressed relative to the control group. Data are presented as mean ± SEM from n = 4 samples. Statistical significance is indicated as p-values interpreted as follows: 0.0332, 0.0021, 0.0002, and <0.0001.^2045201,^1890101,^4133,^1857601,^1723901,^1578201,^1493901,^1486201,^1480801,^1418601,^1260001,^836301,^307801,^221901, ^74501,^22701. Figure S5. Volcano plot depicts the PSI levels forin the ALB experimental comparison. The X-axis represents the difference in PSI valuesfor each ASE, while the Y-axis displays the negative logarithmic FDR. A horizontal dotted line indicates the negative logarithmic value of the FDR cutoff, and two vertical lines represent the absolute ΔPSI value of 0.1. Colored points denote different types of significant DASes, and gray points represent non-significant DAS events. Figure S6. Volcano plot illustrating the PSI levels for significant DASes in the IVC experimental comparison. The X-axis displays the difference in PSI valuesfor each DASes, and the Y-axis shows the negative logarithmic FDR. A horizontal dotted line marks the negative logarithmic value of the FDR cutoff, while two vertical lines indicate the absolute ΔPSI value of 0.1. Colored points represent distinct types of significant DAS events, and gray points represent non-significant ASEs. Figure S7. Volcano plot illustrates the percentage of inclusionlevels for significant DAS events in the PYR experimental comparison. The X-axis displays the difference in PSI valuesfor each ASE, and the Y-axis shows the negative logarithmic FDR. A horizontal dotted line marks the negative logarithmic value of the FDR cutoff, while two vertical lines indicate the absolute ΔPSI value of 0.1. Colored points represent distinct types of significant DAS events, and gray points represent non-significant DAS events. Additional file 2: Table S1. Detailed bioinformatics workflow. Table S2. Comparison of log2FoldChange values between RNA-seq and real timePCR.. Table S3. The table summarizes RNA-seq quality and yield across 16 samples.. Table S4. Differentially expressed genes identified in A. simplex after three medicine treatment . Table S5. Differentially expressed long nonocoding RNA identified in A. simplex after three medicine treatment . Table S6. Correlation between DELs and DEGs after Albendazol treatment. Table S7. Correlation between DELs and DEGs after Ivermectin treatment. Table S8. Correlation between lncRNA and DEGs after Pyrantel treatment. Table S9. DAS events identified after Albendazol, Ivermectin and Pyrantel treatment. Table S10. SNVs indicated difference in allele specific expression (ASE). Table S11.Single nucleotide variation on DNA seqeunces by Nanopore seqeuncing . Table S12. DEGs, DASs and SNVs assignment to GO terms.. Author contributions EŁ-B and IP conceptualized the study. IP and MS developed the methodology. ŁP and MM provided the software. EŁ-B validated the results. EŁ-B conducted the formal analysis and carried out the investigation and provided resources, while ŁP and MM curated the data. MM and EŁ-B wrote the original draft. and EŁ-B performed the review and editing. MM prepared the visualizations. EŁ-B supervised the project, administered the project. IP acquired the funding. All authors reviewed and approved the final manuscript. Funding This work was supported by the National Science Centre of Poland, grant no. 2020/37/N/NZ9/03312. Data availability Transcriptomic data are available at the European Nucleotide Archive (ENA) under accession number PRJEB98681. Declarations Ethics approval and consent to participate Not applicable. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Additional file 1: Figure S1. The Venn diagram illustrates the number of DEGs and the common DEGs in the ALB, IVC, PYRcolor comparisons. Figure S2. The Venn diagram illustrates the number of DELs and the common DELs in the ALB, IVC, PYRcolor comparisons. Figure S3. The results of correlations analysis between RT-PCR method and RNA-Seq. Selected DEGs were marked with different color for each treatment comparison. The Y-axis shows the log2 obtained by the RNA-seq method, while the X-axis shows the log2 of validated DEGs measured by the qPCR method. Details can be found in Additional file 2: Table S2. Figure S4. Relative expression levels of genes in response A. simplexto drug treatmentscompared to control, as determined by quantitative real-time PCR. mRNA expression of each genewas normalized to housekeeping gene expression and expressed relative to the control group. Data are presented as mean ± SEM from n = 4 samples. Statistical significance is indicated as p-values interpreted as follows: 0.0332, 0.0021, 0.0002, and <0.0001.^2045201,^1890101,^4133,^1857601,^1723901,^1578201,^1493901,^1486201,^1480801,^1418601,^1260001,^836301,^307801,^221901, ^74501,^22701. Figure S5. Volcano plot depicts the PSI levels forin the ALB experimental comparison. The X-axis represents the difference in PSI valuesfor each ASE, while the Y-axis displays the negative logarithmic FDR. A horizontal dotted line indicates the negative logarithmic value of the FDR cutoff, and two vertical lines represent the absolute ΔPSI value of 0.1. Colored points denote different types of significant DASes, and gray points represent non-significant DAS events. Figure S6. Volcano plot illustrating the PSI levels for significant DASes in the IVC experimental comparison. The X-axis displays the difference in PSI valuesfor each DASes, and the Y-axis shows the negative logarithmic FDR. A horizontal dotted line marks the negative logarithmic value of the FDR cutoff, while two vertical lines indicate the absolute ΔPSI value of 0.1. Colored points represent distinct types of significant DAS events, and gray points represent non-significant ASEs. Figure S7. Volcano plot illustrates the percentage of inclusionlevels for significant DAS events in the PYR experimental comparison. The X-axis displays the difference in PSI valuesfor each ASE, and the Y-axis shows the negative logarithmic FDR. A horizontal dotted line marks the negative logarithmic value of the FDR cutoff, while two vertical lines indicate the absolute ΔPSI value of 0.1. Colored points represent distinct types of significant DAS events, and gray points represent non-significant DAS events. Additional file 2: Table S1. Detailed bioinformatics workflow. Table S2. Comparison of log2FoldChange values between RNA-seq and real timePCR.. Table S3. The table summarizes RNA-seq quality and yield across 16 samples.. Table S4. Differentially expressed genes identified in A. simplex after three medicine treatment . Table S5. Differentially expressed long nonocoding RNA identified in A. simplex after three medicine treatment . Table S6. Correlation between DELs and DEGs after Albendazol treatment. Table S7. Correlation between DELs and DEGs after Ivermectin treatment. Table S8. Correlation between lncRNA and DEGs after Pyrantel treatment. Table S9. DAS events identified after Albendazol, Ivermectin and Pyrantel treatment. Table S10. SNVs indicated difference in allele specific expression (ASE). Table S11.Single nucleotide variation on DNA seqeunces by Nanopore seqeuncing . Table S12. DEGs, DASs and SNVs assignment to GO terms.. Data Availability Statement Transcriptomic data are available at the European Nucleotide Archive (ENA) under accession number PRJEB98681.